These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Similar names for similar biologics. Casadevall N; Felix T; Strober BE; Warnock DG BioDrugs; 2014 Oct; 28(5):439-44. PubMed ID: 25001080 [TBL] [Abstract][Full Text] [Related]
3. Safety of Biologics, Including Biosimilars: Perspectives on Current Status and Future Direction. Ingrasciotta Y; Cutroneo PM; Marcianò I; Giezen T; Atzeni F; Trifirò G Drug Saf; 2018 Nov; 41(11):1013-1022. PubMed ID: 29796832 [TBL] [Abstract][Full Text] [Related]
4. A Comprehensive Overview on Biosimilars. Kadam V; Bagde S; Karpe M; Kadam V Curr Protein Pept Sci; 2016; 17(8):756-761. PubMed ID: 26916165 [TBL] [Abstract][Full Text] [Related]
5. Biosimilars - terms of use. Declerck P; Mellstedt H; Danese S Curr Med Res Opin; 2015 Dec; 31(12):2325-30. PubMed ID: 26397731 [TBL] [Abstract][Full Text] [Related]
6. Biosimilars: A consideration of the regulations in the United States and European union. Daller J Regul Toxicol Pharmacol; 2016 Apr; 76():199-208. PubMed ID: 26732800 [TBL] [Abstract][Full Text] [Related]
7. Nomenclature and traceability debate for biosimilars: small-molecule surrogates lend support for distinguishable nonproprietary names. Chao J; Skup M; Alexander E; Tundia N; Macaulay D; Wu E; Mulani P Adv Ther; 2015 Mar; 32(3):270-83. PubMed ID: 25772256 [TBL] [Abstract][Full Text] [Related]
8. From bioequivalence to biosimilars: How much do regulators dare? Weise M Z Evid Fortbild Qual Gesundhwes; 2019 Mar; 140():58-62. PubMed ID: 30622000 [TBL] [Abstract][Full Text] [Related]
9. Biosimilar monoclonal antibodies: preclinical and clinical development aspects. Gonçalves J; Araújo F; Cutolo M; Fonseca JE Clin Exp Rheumatol; 2016; 34(4):698-705. PubMed ID: 27383278 [TBL] [Abstract][Full Text] [Related]
10. Biological agents and biosimilars: Essential information for the internist. Pasina L; Casadei G; Nobili A Eur J Intern Med; 2016 Sep; 33():28-35. PubMed ID: 27342030 [TBL] [Abstract][Full Text] [Related]
11. Comparative Safety Profiles of Oncology Biosimilars: A Systematic Review and Network Meta-analysis. Na H; Kwon SH; Son KH; Baek Y; Kim J; Lee EK BioDrugs; 2023 Mar; 37(2):205-218. PubMed ID: 36729329 [TBL] [Abstract][Full Text] [Related]
12. Key considerations in the preclinical development of biosimilars. Bui LA; Hurst S; Finch GL; Ingram B; Jacobs IA; Kirchhoff CF; Ng CK; Ryan AM Drug Discov Today; 2015 May; 20 Suppl 1():3-15. PubMed ID: 25912284 [TBL] [Abstract][Full Text] [Related]
13. Postmarketing Safety of Biosimilars: Current Status, Challenges, and Opportunities in the Spontaneous Reporting System. Singh A; Kalaivani M; Srivastava S; Goyal RK; Gupta SK Ther Innov Regul Sci; 2020 May; 54(3):667-680. PubMed ID: 33301154 [TBL] [Abstract][Full Text] [Related]
14. Biosimilar medical products - licensing, pharmacovigilance and interchangeability. Grozdanova A; Netkovska KA; Sterjev Z; Naumovska Z; Zarevski R; Dimovski A; Suturkova L Pril (Makedon Akad Nauk Umet Odd Med Nauki); 2016; 37(1):27-36. PubMed ID: 27442414 [TBL] [Abstract][Full Text] [Related]
15. Considerations in the early development of biosimilar products. Li EC; Abbas R; Jacobs IA; Yin D Drug Discov Today; 2015 May; 20 Suppl 2():1-9. PubMed ID: 25572407 [TBL] [Abstract][Full Text] [Related]
16. The process defines the product: what really matters in biosimilar design and production? Vulto AG; Jaquez OA Rheumatology (Oxford); 2017 Aug; 56(suppl_4):iv14-iv29. PubMed ID: 28903544 [TBL] [Abstract][Full Text] [Related]
17. Biosimilars-Emerging Role in Nephrology. Wish JB Clin J Am Soc Nephrol; 2019 Sep; 14(9):1391-1398. PubMed ID: 30082337 [TBL] [Abstract][Full Text] [Related]
19. Pharmacovigilance of biosimilars - Why is it different from generics and innovator biologics? Oza B; Radhakrishna S; Pipalava P; Jose V J Postgrad Med; 2019; 65(4):227-232. PubMed ID: 31571620 [TBL] [Abstract][Full Text] [Related]